US-based molecular diagnostics firm Myriad Genetics has introduced a new medical tool, riskScore, to support its myRisk test developed for hereditary cancer.

riskScore is an algorithm designed to combine genetic markers with a patient’s family and clinical history to quantify the risk of breast cancer development.

The tool will combine data from more than 80 genetic markers called single nucleotide polymorphisms (SNPs) throughout the genome with a family and personal history algorithm called Tyrer-Cuzick model.

Myriad Genetics president and CEO Mark Capone said: “Through the years, Myriad has expanded the number of genes tested and demonstrated.

“Now this new test will provide definitive answers to the 90% of patients testing negative for hereditary cancer genes and will be complimentary to patients tested with myRisk.”

"This new test will provide definitive answers to the 90% of patients testing negative for hereditary cancer genes and will be complimentary to patients tested with myRisk."

Researchers at the firm initially optimised the genetic markers in riskScore with more than 100,000 patient samples.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The researchers subsequently completed two statistically significant validation studies assessing the tool’s ability to predict the risk of breast cancer in European patients.

The Myriad myRisk Hereditary Cancer test is a 28-gene panel that can identify the risk of breast, ovarian, gastric, colorectal, pancreatic, melanoma, prostate and endometrial cancers.

In addition to a risk assessment, the simple and easy-to-use test delivers specific medical management recommendations to patients who test either positive or negative according to the guidelines of select professional medical societies.


Image: Myriad Genetics researchers. Photo: courtesy of Myriad Genetics Inc.